ClaimsFiler is reminding Ultragenyx Pharmaceutical Inc. (RARE) investors who sustained losses exceeding $100,000 to file as lead plaintiffs by April 6, 2026, in a securities class action lawsuit. The lawsuit alleges that Ultragenyx failed to disclose material information, specifically regarding the failure of its Phase 3 Orbit and Cosmic studies for setrusumab, which led to a significant 42% stock price drop. Investors who purchased shares between August 3, 2023, and December 26, 2025, are affected.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors
ClaimsFiler is reminding Ultragenyx Pharmaceutical Inc. (RARE) investors who sustained losses exceeding $100,000 to file as lead plaintiffs by April 6, 2026, in a securities class action lawsuit. The lawsuit alleges that Ultragenyx failed to disclose material information, specifically regarding the failure of its Phase 3 Orbit and Cosmic studies for setrusumab, which led to a significant 42% stock price drop. Investors who purchased shares between August 3, 2023, and December 26, 2025, are affected.